Advancing Neuropsychiatric Therapies: Synendos Pipeline
SYT-510: Leading the Way in ECS Modulation
Pioneering Neuropsychiatric Treatment with SYT-510
Developmental Compounds Overview
SYT-520
Currently in preclinical trials, SYT-520 aims to enhance cognitive function and emotional stability through targeted ECS modulation.
SYT-530
In early-stage development, SYT-530 focuses on addressing anxiety disorders with a novel mechanism of action.
SYT-540
Undergoing initial testing, SYT-540 is designed to improve mood regulation and resilience in stress-related conditions.
Development Timeline
Explore the journey of SYT-510 and our other promising compounds as we advance through the stages of drug development.
2018
Company Foundation
Synendos was established with a mission to transform the treatment landscape for neuropsychiatric disorders.
2019
Discovery of SYT-510
Our lead candidate, SYT-510, was identified as a promising ECS modulator with potential therapeutic benefits.
2020
Preclinical Success
SYT-510 demonstrated significant efficacy and safety in preclinical trials, paving the way for clinical studies.
2021
Phase I Clinical Trials
Initiated Phase I trials to evaluate the safety and pharmacokinetics of SYT-510 in healthy volunteers.
Innovative Drug Class
Key Features of SERIs
Targeted ECS Modulation
SERIs selectively inhibit endocannabinoid reuptake, offering a novel approach to restoring brain function.
Self-limiting Action
Our drugs provide a balanced modulation of the ECS, reducing the risk of overstimulation and side effects.
Broad Therapeutic Potential
SERIs have applications across various neuropsychiatric disorders, promising wide-reaching patient benefits.
First-in-Class Innovation
As pioneers in ECS modulation, our therapies represent a new frontier in neuroscience treatment.
Patient-centric Development
Our focus is on creating therapies that improve quality of life with minimal disruption to daily activities.
Sustainable Impact
We aim to deliver long-term solutions that address the root causes of neuropsychiatric conditions.
Expert Endorsements
„Synendos‘ approach to ECS modulation is groundbreaking and holds immense promise for patients with unmet needs.“
Dr. Emily Carter
„The development of SYT-510 is a significant leap forward in treating neuropsychiatric disorders with precision and care.“
Prof. John Smith
„I am excited about the potential of SERIs to revolutionize how we approach mental health treatment.“
Dr. Sarah Lee
Stay Informed on Our Drug Development Journey
Join our community to receive the latest updates on Synendos‘ groundbreaking research and the progress of our lead candidate, SYT-510. Subscribe today to be at the forefront of innovations in neuropsychiatric treatment.